|
|
|
Fibrogen Inc (NASDAQ: FGEN) |
|
|
|
|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of Fibrogen Inc's Business Segments
Fibrogen Inc. is a biopharmaceutical company that focuses on addressing serious unmet medical needs through the development and commercialization of innovative therapies across multiple segments. Its focus on research and product development aims to create breakthrough treatments that improve patient outcomes in various critical health areas. Here is a detailed overview of the segments, products, and services offered by Fibrogen:
1. Anemia and Fibrosis Treatment
Products:
- Roxadustat: This is Fibrogens leading anemia treatment aimed at managing anemia of chronic kidney disease (CKD). Roxadustat operates through a novel mechanism by inhibiting hypoxia-inducible factors (HIF), which enhances erythropoiesis and iron metabolism, thus increasing hemoglobin levels in patients with CKD. Its oral administration provides a convenient option for patients, contrasting the traditional intravenous methods.
- Tissue-Specific Pan-TGF-beta Inhibitor: Fibrogen is also developing a compound that targets transforming growth factor-beta (TGF-beta), a signaling pathway implicated in the progression of fibrosis in various tissues. This inhibitor has the potential to treat patients with advanced fibrosis conditions, which are often associated with poor prognoses.
Services:
- Fibrogen provides patient support services to assist those undergoing treatment for anemia and related conditions, including educational resources and access to specialized care.
- The company collaborates with healthcare providers to enhance patient identification and management strategies.
Cancer Immunotherapy
Products:
- Pamrevlumab: This monoclonal antibody is at the forefront of Fibrogen's cancer immunotherapy efforts. Pamrevlumab targets the connective tissue growth factor (CTGF), which is involved in tumor growth and progression. The therapy is under investigation for various cancers, including pancreatic and gastric cancer, adding to its potential utility in treating a broad range of solid tumors by enhancing the immune systems anti-tumor response.
Services:
- Fibrogen engages in collaborative partnerships to develop and test new immunotherapy treatments, leveraging the expertise of research institutions and other biotechnology companies.
- They focus on conducting clinical trials to assess the safety and efficacy of their therapies, with ongoing studies aimed at expanding the indication and use of pamrevlumab.
Gene Therapy and Rare Diseases
Products:
- ARA 290: This innovative molecule is being developed as a restorative therapy targeting rare and orphan diseases. ARA 290 acts through a pathway that may provide regenerative benefits to patients with conditions characterized by nerve and tissue damage, making it crucial for patients with limited therapeutic options.
Services:
- Fibrogen is dedicated to advancing gene therapy initiatives, aiming to leverage its scientific expertise to tackle rare diseases and develop biologics that can provide effective treatment options where few exist.
- The company collaborates with academic and research institutions to identify new therapeutic targets and develop cutting-edge methodologies for gene therapy.
Overall Portfolio and Commitment
Fibrogen Inc. maintains a strong commitment to research and innovation in biopharmaceuticals, with a diverse portfolio of products and services tailored to meet the needs of patients facing serious health challenges. Their ongoing focus on anemia, fibrosis, cancer immunotherapy, and rare diseases ensures that they remain at the forefront of developing therapies that can significantly impact patient care and clinical outcomes. By continuously investing in research and forging strategic partnerships, Fibrogen aims to deliver transformative therapies that address critical health needs across different patient populations.
Composition of Fibrogen Inc Revenues by
Segments |
| |
| China |
|
 565.9 % |
of total Revenue |
| AstraZeneca Agreements |
|
1347.21 % |
of total Revenue |
| Drug Product Revenue Net |
|
94.74 % |
of total Revenue |
| Drug Product Revenue Net Astellas Agreement |
|
94.93 % |
of total Revenue |
| Drug Product Revenue Net Astellas Agreement Japan |
|
65.02 % |
of total Revenue |
| Drug Product Revenue Net Astellas Agreement Europe |
|
29.72 % |
of total Revenue |
Q1 three months ended (Mar 31 2025)
|
| Revenues by Business Segments |
Revenues
(in millions $) |
%
(of total Revenues) |
| China |
15.50 |
565.9 % |
| AstraZeneca Agreements |
36.90 |
1347.21 % |
| Drug Product Revenue Net |
2.60 |
94.74 % |
| Drug Product Revenue Net Astellas Agreement |
2.60 |
94.93 % |
| Drug Product Revenue Net Astellas Agreement Japan |
1.78 |
65.02 % |
| Drug Product Revenue Net Astellas Agreement Europe |
0.81 |
29.72 % |
| Total |
2.74 |
100 % |
Q1 three months ended (Mar 31 2025)
|
| Revenue Growth rates by Segment |
Y/Y Revenue
% |
Q/Q Revenue
% |
| China |
- |
- |
| AstraZeneca Agreements |
36.16 % |
- |
| Drug Product Revenue Net |
-89.4 % |
- |
| Drug Product Revenue Net Astellas Agreement |
- |
- |
| Drug Product Revenue Net Astellas Agreement Japan |
- |
- |
| Drug Product Revenue Net Astellas Agreement Europe |
-20.27 % |
- |
| Total |
-95.1 % |
-90.75 % |
Q1 three months ended (Mar 31 2025)
|
| Income by Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
4.64 |
169.37 % |
Q1 three months ended (Mar 31 2025)
|
| Income Growth rates by Segment |
Y/Y Income
% |
Q/Q Income
% |
| Total |
- |
- |
Annual Report on Fibrogen Inc Divisions, Sales by Country |
| |
| China |
|
0.31 % |
of total Revenue |
| AstraZeneca Agreements |
|
536.78 % |
of total Revenue |
| AstraZeneca Agreements China |
|
67.18 % |
of total Revenue |
| Development Revenue |
|
6.58 % |
of total Revenue |
| Astellas Agreement License Revenue Europe |
|
4.71 % |
of total Revenue |
| AstraZeneca Agreements Development Revenue U S RoW and China |
|
1.41 % |
of total Revenue |
| AstraZeneca Agreements U S RoW and China Product |
|
1197.8 % |
of total Revenue |
| Other Revenue - Contract Manufacturing |
|
6.58 % |
of total Revenue |
| Other Revenue - Contract Manufacturing Eluminex |
|
0.39 % |
of total Revenue |
| United States |
|
88.16 % |
of total Revenue |
| Europe |
|
21.17 % |
of total Revenue |
| Japan |
|
-9.64 % |
of total Revenue |
Twelve months ended 2024
|
| FGEN s Annual Revenue by Geography and Business Segments |
Sales
(in millions $) |
%
(of total Sales) |
| China |
0.09 |
0.31 % |
| AstraZeneca Agreements |
159.00 |
536.78 % |
| Total |
29.62 |
100 % |
| AstraZeneca Agreements China |
19.90 |
67.18 % |
| Development Revenue |
1.95 |
6.58 % |
| Astellas Agreement License Revenue Europe |
1.40 |
4.71 % |
| AstraZeneca Agreements Development Revenue U S RoW and China |
0.42 |
1.41 % |
| AstraZeneca Agreements U S RoW and China Product |
354.80 |
1197.8 % |
| Other Revenue - Contract Manufacturing |
1.95 |
6.58 % |
| Other Revenue - Contract Manufacturing Eluminex |
0.12 |
0.39 % |
| United States |
26.11 |
88.16 % |
| Europe |
6.27 |
21.17 % |
| Japan |
-2.85 |
-9.64 % |
Twelve months ended 2024
|
| FGEN s Annual Income by Country and Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
-47.58 |
- |
Twelve months ended 2024
|
| Annual Revenue and Income Growth by Country and Business Segments |
% Y/Y Sales Growth |
% Y/Y Income Growth |
| China |
-98.92 % |
- |
| AstraZeneca Agreements |
-11.59 % |
- |
| Drug Product Revenue Net |
- |
- |
| Total |
-79.95 % |
- |
| AstraZeneca Agreements China |
468.57 % |
- |
| Development Revenue |
-89.41 % |
- |
| Astellas Agreement License Revenue Europe |
-78.38 % |
- |
| AstraZeneca Agreements Development Revenue U S RoW and China |
-95.59 % |
- |
| Other Revenue - Contract Manufacturing |
-89.41 % |
- |
| Other Revenue - Contract Manufacturing Eluminex |
-87.89 % |
- |
| United States |
101.48 % |
- |
| Europe |
-34.34 % |
- |
| Japan |
- |
- |
| License Revenue |
- |
- |
| AstraZeneca Agreements License Revenue U S RoW and China |
- |
- |
| License Revenue Eluminex |
- |
- |
| Other Revenue - Patent Transfer Eluminex |
- |
- |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
